IDEXX LABORATORIES INC /DE Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
IDEXX LABORATORIES INC /DE (IDXX) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of $0 for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-10-31.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2024-10-31
- IDEXX LABORATORIES INC /DE fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2024-09-30 was $0.00.
- IDEXX LABORATORIES INC /DE fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2023-12-31 was $0.00.
- IDEXX LABORATORIES INC /DE fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2023-09-30 was -$21.00K.
- IDEXX LABORATORIES INC /DE fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2022-03-31 was $0.00.
- IDEXX LABORATORIES INC /DE fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2023 was -$21.00K.
- IDEXX LABORATORIES INC /DE fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- IDEXX LABORATORIES INC /DE fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2021 was $2.00M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|
| 2024-09-30 | $0.00 10-Q · filed 2024-10-31 | $0.00 10-Q · filed 2024-10-31 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$21.00K derived: sum of 2 quarters · filed 2024-10-31 | -$21.00K 10-K · filed 2024-02-22 | |
| 2023-09-30 | -$21.00K 10-Q · filed 2024-10-31 | -$21.00K 10-Q · filed 2024-10-31 | ||
| 2022-12-31 | $0.00 10-K · filed 2024-02-22 | |||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-04 | $2.00M derived: sum of 2 quarters · filed 2022-05-04 | ||
| 2021-12-31 | $2.00M 10-K · filed 2022-02-16 | $2.00M 10-K · filed 2022-02-16 | ||
| 2021-09-30 | $0.00 10-Q · filed 2021-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | United States | $6.510B | 26.31 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |